

19 May 2023

Diaceutics PLC
("Diaceutics" or "the Company")

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, announces the issue of 1,276,707 share options over ordinary shares of £0.002 each in the Company ("**Share Options**") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("**ESOP**"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.

Share Options were granted as follows:

<i>Name</i>	<i>Number of Share Options granted</i>	<i>Total no. of ordinary shares under option post grant</i>	<i>% of existing issued share capital</i>	<i>Effective Grant date</i>
Peter Keeling, CEO	102,468	435,313	0.52%	18 May 2023
Nick Roberts, CFO	67,034	158,872	0.19%	18 May 2023
Ryan Keeling, CIO	93,407	409,851	0.49%	18 May 2023
Julie Browne, COO and PDMR	67,109	169,047	0.20%	18 May 2023
Jordan Clark, CCO and PDMR	65,245	115,740	0.14%	18 May 2023
Susanne Munksted, CPO and PDMR	68,834	249,199	0.30%	18 May 2023
Other employees (43 persons)	812,610	1,675,537	1.98%	18 May 2023

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "**Performance Period**"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth in the proportion of subscription revenue and Total Shareholder Return ("**TSR**") during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to 18 May 2023. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the Company is 3,826,487 representing approximately 4.52% of its current issued share capital of 84,461,386.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison, Nick Harland, Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR

Caroline Forde, Kieran Breheny, Matthew Young

Tel: +44(0)20 3405 0205

diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Peter Keeling				
2 Reason for notification						
a.	Position/Status	Chief Executive Officer, Director				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>102,468</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	102,468
Price(s)	Volume(s)					
Exercise price of 0.2p per share	102,468					
e.	Date of the transaction	18 May 2023				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Nick Roberts
2 Reason for notification		

a.	Position/Status	Chief Finance Officer, Director				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>67,034</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	67,034
Price(s)	Volume(s)					
Exercise price of 0.2p per share	67,034					
e.	Date of the transaction	18 May 2023				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name	Ryan Keeling				
2	Reason for notification					
a.	Position/Status	Chief Innovation Officer, Director				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)		
Price(s)	Volume(s)					

		<table border="1"> <tr> <td>Exercise price of 0.2p per share</td> <td>93,407</td> </tr> </table>	Exercise price of 0.2p per share	93,407
Exercise price of 0.2p per share	93,407			
e.	Date of the transaction	18 May 2023		
f.	Place of the transaction	Outside a trading venue		

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Julie Browne				
2 Reason for notification						
a.	Position/Status	Chief Operations Officer and PDMR				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>67,109</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	67,109
Price(s)	Volume(s)					
Exercise price of 0.2p per share	67,109					
e.	Date of the transaction	18 May 2023				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Jordan Clark
2 Reason for notification		
a.	Position/Status	Chief Commercial Officer and PDMR
b.	Initial notification/ Amendment	Initial

	Amendment					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>65,245</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	65,245
Price(s)	Volume(s)					
Exercise price of 0.2p per share	65,245					
e.	Date of the transaction	18 May 2023				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name	Susanne Munksted				
2	Reason for notification					
a.	Position/Status	Chief Precision Medicine Officer and PDMR				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>68,834</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	68,834
Price(s)	Volume(s)					
Exercise price of 0.2p per share	68,834					

e.	Date of the transaction	18 May 2023
f.	Place of the transaction	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHKKLBFXELFBBZ